738 related articles for article (PubMed ID: 25475577)
1. A critical look at local-regional management of peritoneal metastasis.
Chan CH; Cusack JC; Ryan DP
Hematol Oncol Clin North Am; 2015 Feb; 29(1):153-8. PubMed ID: 25475577
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
4. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R
Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
[TBL] [Abstract][Full Text] [Related]
6. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
8. Management of colorectal cancer patients at high risk of peritoneal metastases.
Shariff U; Seretis C; Youssef H
J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.
Ahmed S; Stewart JH; Shen P; Votanopoulos KI; Levine EA
J Surg Oncol; 2014 Oct; 110(5):575-84. PubMed ID: 25164477
[TBL] [Abstract][Full Text] [Related]
11. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
13. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit?
Rivard JD; McConnell YJ; Temple WJ; Mack LA
J Surg Oncol; 2014 Feb; 109(2):104-9. PubMed ID: 24449172
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Riss S; Mohamed F; Dayal S; Cecil T; Stift A; Bachleitner-Hofmann T; Moran B
Eur J Surg Oncol; 2013 Sep; 39(9):931-7. PubMed ID: 23810280
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
Trials; 2010 May; 11():62. PubMed ID: 20500867
[TBL] [Abstract][Full Text] [Related]
16. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis.
Hall B; Padussis J; Foster JM
Surg Clin North Am; 2017 Jun; 97(3):671-682. PubMed ID: 28501254
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
19. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
Cortes-Guiral D; Elias D; Cascales-Campos PA; Badía Yébenes A; Guijo Castellano I; León Carbonero AI; Martín Valadés JI; Garcia-Foncillas J; Garcia-Olmo D
World J Gastroenterol; 2017 Jan; 23(3):377-381. PubMed ID: 28210074
[TBL] [Abstract][Full Text] [Related]
20. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]